Form 4: Relay Therapeutics CEO Sanjiv Patel Executes Stock Option and Sells Shares Under 10b5-1 Plan

Relay Therapeutics' CEO, Sanjiv Patel, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On July 25 and 26, 2024, Sanjiv Patel, the President and CEO of Relay Therapeutics, executed transactions involving the company's common stock.
• Patel exercised stock options to acquire 50,000 shares on July 25 and 36,706 shares on July 26, both at an exercise price of $5.04 per share.
• Simultaneously, Patel sold 50,000 shares on July 25 at a weighted average price of $9.16 and 36,706 shares on July 26 at a weighted average price of $9.07.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2024.
• Following these transactions, Patel directly owns 766,130 shares of Relay Therapeutics common stock, which includes 762,360 shares underlying restricted stock units.
• Patel also has indirect ownership of 674,548 shares through The Patel Family Irrevocable Trust of 2019 and 687,355 shares through The SSP Irrevocable Trust of 2020.
• He also directly owns options to buy 482,073 shares.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing insider transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about stock option exercises and sales. The use of a 10b5-1 plan suggests a neutral, pre-planned approach.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It's common for executives to exercise stock options and sell shares, often under pre-arranged trading plans like Rule 10b5-1, to manage their personal finances. The market will likely assess the transactions in the context of Relay Therapeutics' overall performance and future prospects.

Comparison to Industry Standards

• Insider transactions are common across publicly traded companies, particularly in the biotech sector where stock options are a significant part of executive compensation.
• The use of a 10b5-1 trading plan is a standard practice to avoid accusations of insider trading, aligning with best practices observed at companies like Amgen, Gilead, and Vertex.
• The size and frequency of these transactions are typical for CEOs managing their equity holdings, similar to patterns seen at comparable firms such as BioMarin or Incyte.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, depending on how the market interprets the insider selling.
• The impact on employees, customers, suppliers, and creditors is likely to be negligible, as these are routine financial transactions by an executive.

Key Dates